The Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Glioblastoma Multiforme (GBM) Treatment Market:
According to The Business Research Company’s Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024, The glioblastoma multiforme (gym) treatment market size has grown rapidly in recent years. It will grow from $2.23 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increased incidence and prevalence, advancements in diagnostic techniques, clinical trials and research funding, collaborations and partnerships, improved understanding of tumor biology.
The glioblastoma multiforme (gym) treatment market size is expected to see rapid growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to emergence of immunotherapies, precision medicine advancements, expanded knowledge of genetic markers, patient advocacy and awareness, government support for rare diseases. Major trends in the forecast period include exploration of combination therapies, integration of artificial intelligence in diagnosis and treatment planning, rise in adoption of immunotherapeutic approaches, advance medical tools and equipment.
The increasing prevalence of brain disorders is expected to propel the growth of the glioblastoma multiforme (GBM) treatment market going forward. Brain disorders refer to abnormal functioning of the brain as well as the nerves found throughout the human body and the spinal cord. The increasing prevalence of brain disorders such as glioblastoma multiforme (GBM) is due to various contributing factors such as the aging population, compromised immune systems, overdiagnosis, ionizing radiation, air pollution, and others which creates the need for the treatment of brain disorders to improve well-being. For instance, according to the report published by Globocan, a US-based international agency for providing global cancer statistics, approximately 308,102 cancer cases were detected for the brain and central nervous system, and 251,329 deaths in the year 2020 globally. Additionally, according to a report published by the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, in 2022, it is estimated around 25,050 malignant tumors of the brain or spinal cord cancer cases will be diagnosed in the US. Therefore, the increasing prevalence of brain disorders is driving the growth of the glioblastoma multiforme (GBM) treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp
The glioblastoma multiforme (GBM) treatment market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
Major companies operating in the glioblastoma multiforme treatment market are focusing on innovative treatments such as radiopharmaceutical therapy to meet the demand for advanced and targeted therapeutic solutions. Radiopharmaceutical therapy involves the use of radioactive substances to treat diseases by delivering targeted radiation to specific tissues or cells. It is often used in cancer treatment to destroy cancer cells. For instance, in February 2022, Theragnostics, a UK-based provider of molecular radiotherapy and molecular imaging diagnostic products, announced that innovative I-123 PARPi (THG-009) therapy, granted an Innovation Passport by the UK MHRA, aims to address primary and recurrent Glioblastoma Multiforme (GBM). Theragnostics’ encouraging preclinical findings are propelling I-123 PARPi into a Phase 1 clinical trial for treating recurrent GBM.
The glioblastoma multiforme (gbm) treatment market report table of contents includes:
1. Executive Summary
2. Glioblastoma Multiforme (GBM) Treatment Market Characteristics
3. Glioblastoma Multiforme (GBM) Treatment Market Trends And Strategies
4. Glioblastoma Multiforme (GBM) Treatment Market – Macro Economic Scenario
5. Global Glioblastoma Multiforme (GBM) Treatment Market Size and Growth
.
.
.
26. South America Glioblastoma Multiforme (GBM) Treatment Market
27. Brazil Glioblastoma Multiforme (GBM) Treatment Market
28. Middle East Glioblastoma Multiforme (GBM) Treatment Market
29. Africa Glioblastoma Multiforme (GBM) Treatment Market
30. Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape And Company Profiles
Top Major Players:
- fizer Inc
- F. Hoffmann-La Roche AG
- Merck & Co. Inc
- AbbVie Inc
- Novartis AG
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
